abstract Stem cells have long been in focus as potential therapy or even cure for a whole myriad of diseases. Many neurodegenerative disorders, both acute and chronic, are characterized by irreversible neuronal damage and loss, and only a few efficient treatment options exist. In contrast to many other tissues, the potential of selfregeneration of the central nervous system is highly limited. There is hope that stem cells could replace the damaged neuronal and glial cells, and provide biological and functional restoration based on their properties of self renewal and the ability to give rise to different cells. In recent years, the promising results of research on animal models has led to the establishment of the first clinical trials; although no clear evidence of therapeutic benefit for any of the conditions have been ascertained. Here we give a review of the current strategies of stemcell based therapy for some of the more common neurological disorders, discussing the progress and current challenges, and giving an overview of future perspectives.
introduction
There are two basic types of stem cells: 1. proven that "traditional" stem cells, such as neural, embryonic, bone marrow mesenchymal, and human umbilical cord blood-derived stem cells can successfully yield neurons, oligodendrocytes and astrocytes [1, 2] . A novel approach in the field has been the introduction of induced-pluripotent stem cells, reprogrammed from patients' somatic cells [3] , providing both an excellent source for human disease modeling [4] [5] [6] , and a potential for patient-specific transplantational therapy, all the while without the ethical controversies and immune rejection associated with pluripotent embryonic stem cells [7] .
Another way to achieve cell replacement is to induce the activity of endogenous neural stem cells located in the central nervous system. These are found in the subventricular zone of the lateral ventricles [8, 9] and the dentate gyrus of the hippocampus [10] , and are responsible for neurogenesis throughout the lifetime [11] [12] [13] [14] . A pathological process such as stroke [15] , traumatic brain injury [16] or inflammatory demyelination [17] stimulates this formation of new neurons. However, this process is stimulated only to a certain degree which is insufficient for regeneration and functional recovery. It is believed that neurogenesis can also be induced by stem cell transplantation [18, 19] . It has been noted that transplanted stem cells which have not differentiated into neural or glial cells or have not survived in the brain, have still provided beneficial functional improvements [20] The proposed mechanism of action is the secretion of trophic factors which may have neuroprotective activity,reduce local inflammation or promote remyelination [21, 22] .
varying results [23] . Stem cells could provide a more reliable and available alternative as a source of dopaminergic neurons [24] Although studies have so far been limited to only a small number of patients, the results are promising. In autologous stem cell transplantation, significant clinical improvement may be expected [25, 26] , albeit the effect seems to diminish after a few years [27] . No significant adverse effects have been reported; and apart from the adverseeffects associated with all stem-cell therapy, there is the possibility of developing dyskinesias, as observed with embryonic mesencephalic grafts [28] . Finally, Parkinson's disease is a complex degenerative process and to focus treatment solely on the restoration of the nigrostriatal dopaminergic system may be an oversimplification [29] and methods which also provide neuroprotection should be sought. Huntington's disease A possible mechanism is the protection of endogenous neurons by cytokine production, while further possibility includes modifying the stem cells before transplantation in order to overproduce neurotrophic factors [34] .
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive upper and lower motor neuron disease which is often rapid in progression with most cases resulting in death a few years after its onset. As there is no effective treatment, stem cell therapy gives great hope to scientists, clinicians and patients [35] . Recent focus has shifted from replacing the damaged motor neuron to providing a "healthy" glial environment which appears to be more important for slowing disease progression [36] , as shown in mutant rodent studies [37, 38] . Several clinical trials are currently being conducted. Phase I of intrathoracic transplantation of mesenchymal stem cells proved to cause no serious adverse effects, although there was no significant clinical benefit [39] , possibly explained by a lack of crucial motoric functions of this cord segment.
Changing the graft location to the motor cortex [40] or cervical cord [41] to all those areas [21] . This explains the current focus on establishing a microenvironment which supports endogenous remyelination [44, 45] .
Another approach is to target the auto- Safety has been assessed by a few studies with a small number of patients using bone marrow derived cells, and reporting no serious adverse effects [54, 55] . The main concerns though are possible tumor formation and increased chance of allodynic pain after transplantation, explained by aberrant axonal regeneration [56, 57] . 
discussion and conclusions
As certain neurological diseases currently angiogenesis [22] .
